At #ESMO26, Dr. Natasha Leighl discussed “SAFFRON: A New Spice in the Post-Osimertinib Landscape.”

Her focus: MET-driven resistance, the rationale for dual EGFR/MET targeting, and why MET amplification (FISH) and protein overexpression (IHC) need careful testing.

SAFFRON: osimertinib + savolitinib vs chemotherapy improved median PFS (7.6 vs 5.4 mo), OS (17.8 vs 12.9 mo), and response (51% vs 27%).

#lcsm #MET